Related Experiment Video
Updated: Jun 2, 2026

Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation
Published on: November 10, 2023
[Bronchiolitis. We know what is the reason and how to treat]
1Oddział Pulmonologii, Alergologii i Dermatologii. Klinika Chorób Dzieci CM UJ, Kraków. milis@cyf-kr.edu.pl
Insights
Bronchiolitis, a common infant respiratory illness, is often caused by viruses like RSV. Nebulized hypertonic saline shows promise in improving outcomes for this condition.
Area of Science:
- Pediatrics
- Respiratory Medicine
- Infectious Diseases
Context:
- Bronchiolitis is a frequent respiratory illness in infants and young children.
- Diagnosis is primarily clinical, with lab tests assessing severity.
- Viral infections, notably RSV and rhinovirus, are the primary cause.
Purpose:
- To review current treatment controversies and emerging therapies for bronchiolitis.
- To evaluate the efficacy and safety of nebulized hypertonic saline.
- To inform clinical practice regarding bronchiolitis management.
Summary:
- Inflammation in bronchiolitis involves edema, epithelial necrosis, mucus production, and potential bronchospasm.
- Established treatments like bronchodilators, steroids, and antivirals lack proven efficacy.
- Nebulized hypertonic saline demonstrates potential to alter the disease course favorably.
Impact:
- Nebulized hypertonic saline offers a potentially effective and safe treatment option.
- This approach may lead to routine acceptance in pediatric bronchiolitis care.
- Improved management can enhance patient outcomes and reduce healthcare burdens.
Abstract:
Bronchilitis is one of the most common respiratory diseases in infants and early childhood (< 2 ys of age). The diagnosis is clinical and laboratory tests support only recognition of the severity level of the disease. In most cases, the main reason of inflammation are viruses: RSV, rhinovirus. In the terminal bronchioles, inflammation process includes: edema, necrosis of epithelial cells, production of mucus, and possibly some degree of bronchospasm. For decades, controversy has surrounded the treatment of bronchiolitis. Last published consensuses and reviews indicate that use of bronchodilators, antibiotics, steroids systemic or inhaled, montelukast, ribavirin does not improve the symptoms of disease and is not routinely recommended. Recent studies suggest that nebulized hypertonic saline may substantially modify the course of disease. Moreover, there are no significant or frequent adverse effects noted in this treatment. It is believed that increased hydration of the airway mucus with inhalation of NaCl solutions will be routinely accepted treatment of children with bronchiolitis.
Related Concept Videos
Pulmonary Cycle: Exhalation
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Respiratory Syncytial Virus Disease
Other Pulmonary Disorders
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
